Tafamidis treatment and neuropsychiatric dysfunction in patients with cardiac aTTR: a post-hoc analysis of the ATTRACT trial

2025/10/15 by Lark Steafo, Ujala Zubair, Julie George +1 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Amyloidosis: Diagnosis, Treatment, Outcomes #Coagulation, Bradykinin, Polyphosphates, and Angioedema #Peptidase Inhibition and Analysis

paper · doi:10.1080/13506129.2025.2564232

openalex publication_date 2025/10/15 · openalex created_date 2025/10/16 · openalex updated_date 2026/06/15

Abstract

Transthyretin cardiac amyloidosis (aTTR), is a debilitating condition characterised by the deposition of amyloid fibrils in the heart, leading to restrictive cardiomyopathy and heart failure. Beyon...

Discussions

• Congratulations to Joel Skaistis of Corewell Health on your public disclosure, “Tafamidis treatment and neuropsychiatric dysfunction in patients with cardiac aTTR: a post-hoc analysis of the ATTRACT t [bsky, 1 points, 0 comments]

Related

• Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
• Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry
• Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry
• A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
• Myocardium From Patients With ATTR Amyloidosis Produces Less Force Secondary to Increased Fibrosis